BOTHELL, Wash.--(Business Wire)--
Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK), in compliance
with Nasdaq Marketplace Rule 4350(b)(1)(B), which requires separate
disclosure of receipt of an audit opinion that contains a going
concern qualification, disclosed that our Annual Report (Form 10-K)
for the year ended December 31, 2007 contains a going concern
qualification from our independent registered public accounting firm,
KPMG LLP.
This announcement does not represent any change or amendment to
our 2007 financial statements or to our Annual Report, filed on Form
10-K with the SEC, on March 17, 2008.
About Nastech
Nastech is a clinical-stage biopharmaceutical company focusing on
the development and commercialization of innovative therapeutic
products based on its proprietary molecular biology-based nasal drug
delivery technology and its proprietary ribonucleic acid interference
technology. Nastech and its collaboration partners are developing
products for multiple therapeutic areas including diabetes, obesity,
osteoporosis, autism, respiratory diseases and inflammatory
conditions. Additional information about Nastech is available at
http://www.nastech.com.
Nastech Forward Looking Statements
Statements made in this press release may be forward-looking
statements within the meaning of Federal Securities laws that are
subject to certain risks and uncertainties and involve factors that
may cause actual results to differ materially from those projected or
suggested. Factors that could cause actual results to differ
materially from those in forward-looking statements include, but are
not limited to: (i) the ability of Nastech or a subsidiary to obtain
additional funding; (ii) the ability of Nastech or a subsidiary to
attract and/or maintain manufacturing, research, development and
commercialization partners; (iii) the ability of Nastech, a subsidiary
and/or a partner to successfully complete product research and
development, including preclinical and clinical studies and
commercialization; (iv) the ability of Nastech, a subsidiary and/or a
partner to obtain required governmental approvals; and (v) the ability
of Nastech, a subsidiary and/or a partner to develop and commercialize
products that can compete favorably with those of competitors.
Additional factors that could cause actual results to differ
materially from those projected or suggested in any forward-looking
statements are contained in Nastech's most recent periodic reports on
Form 10-K and Form 10-Q that are filed with the Securities and
Exchange Commission. Nastech assumes no obligation to update and
supplement forward-looking statements because of subsequent events.
Nastech Pharmaceutical Company Inc.
Matthew D. Haines, Senior Director, Investor Relations
and Corporate Communications, 212-209-3874
ir@nastech.com
Copyright Business Wire 2008
